Pancreatic Cancer Research

ResearcherHiroshima UniversityActive in the last 2 years

Goro Honda

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-1162-4535; OpenAlex author ID A5047536070. Sources: OpenAlex.

Their work

Papers
29 (first author 3, last author 3)
Trials
0
Grants
0
Labs led
1
Collaborators
120
Papers, trials and grants by year

2013: 1 paper · 2014: 1 paper · 2015: 4 papers · 2016: 4 papers · 2017: 2 papers · 2018: 1 paper · 2019: 5 papers · 2020: none · 2021: 1 paper · 2022: 1 paper · 2023: 1 paper · 2024: none · 2025: 6 papers · 2026: 2 papers

Papers 29

  1. Aso Visual Abstract: Comparison between Neoadjuvant Chemoradiotherapy and Chemotherapy for Patients with Resectable Pancreatic Cancer. Co-author DOI 10.1245/s10434-025-18555-4↗
  2. Diagnostic Method Advancement to Improve the Prognosis of Pancreatic Ductal Adenocarcinoma. Last author DOI 10.3390/diagnostics16142286↗
  3. Optimal treatment strategy for patients with pancreatic cancer having positive peritoneal cytology: A nationwide multicenter retrospective cohort study supervi… Co-author DOI 10.1002/jhbp.12074↗
  4. Patients With Pancreatic Cancer With Synchronous Liver Oligometastasis Show a Significant Long-Term Survival Benefit From Resection Under Specific Conditions: … Co-author DOI 10.1002/jhbp.12181↗
  5. Preliminary assessment of TNM classification performance for pancreatic cancer in Japanese radiology reports using GPT-4. Co-author DOI 10.1007/s11604-024-01643-y↗
  6. The impact of neoadjuvant therapy in patients with left-sided resectable pancreatic cancer: an international multicenter study. Co-author DOI 10.1016/j.annonc.2024.12.015↗
  7. Focal pancreatic parenchymal atrophy could be a precursor of pancreatic cancer. Last author DOI 10.1016/j.pan.2025.01.003↗
  8. Comparison between Neoadjuvant Chemoradiotherapy and Chemotherapy for Patients with Resectable Pancreatic Cancer. Co-author DOI 10.1245/s10434-025-17988-1↗
  9. The outcome of a multidisciplinary approach incorporating neoadjuvant chemoradiotherapy with S1 for resectable pancreatic ductal adenocarcinoma. First author DOI 10.1002/ags3.12624↗
  10. Randomized phase III trial of intravenous and intraperitoneal paclitaxel with S-1 versus gemcitabine plus nab-paclitaxel for pancreatic ductal adenocarcinoma w… Co-author DOI 10.1186/s13063-022-06049-7↗
  11. Tolerability of Nab-Paclitaxel Plus Gemcitabine as Adjuvant Setting in Japanese Patients With Resected Pancreatic Cancer: Phase I Study. Co-author DOI 10.1097/mpa.0000000000001702↗
  12. Sustained Elevation of Postoperative Serum Level of Carbohydrate Antigen 19-9 is High-Risk Stigmata for Primary Hepatic Recurrence in Patients with Curatively … Co-author DOI 10.1007/s00268-018-4814-4↗
  13. A single-arm, phase II trial of neoadjuvant gemcitabine and S1 in patients with resectable and borderline resectable pancreatic adenocarcinoma: PREP-01 study. Co-author DOI 10.1007/s00535-018-1506-7↗
  14. Randomized phase II/III trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer (Prep-02/JSAP05). Co-author DOI 10.1093/jjco/hyy190↗
  15. Decreased serum carbohydrate antigen 19-9 levels after neoadjuvant therapy predict a better prognosis for patients with pancreatic adenocarcinoma: a multicente… Co-author DOI 10.1186/s12885-019-5460-4↗
  16. Proposal for Endoscopic Ultrasonography Classification for Small Pancreatic Cancer. Co-author DOI 10.3390/diagnostics9010015↗
  17. Is distal pancreatectomy with en-bloc celiac axis resection effective for patients with locally advanced pancreatic ductal adenocarcinoma? -Multicenter surgica… Co-author DOI 10.1016/j.pan.2017.11.005↗
  18. Retrospective Study of the Correlation Between Pathological Tumor Size and Survival After Curative Resection of T3 Pancreatic Adenocarcinoma: Proposal for Recl… First author DOI 10.1007/s00268-017-4077-5↗
  19. Multicenter Phase II Study of Intravenous and Intraperitoneal Paclitaxel With S-1 for Pancreatic Ductal Adenocarcinoma Patients With Peritoneal Metastasis. Co-author DOI 10.1097/sla.0000000000001705↗
  20. Prognosis after surgical treatment for pancreatic cancer in patients aged 80 years or older: a multicenter study. Co-author DOI 10.1002/jhbp.320↗
  21. Grade B pancreatic fistulas do not affect survival after pancreatectomy for pancreatic cancer: A multicenter observational study. Co-author DOI 10.1016/j.surg.2016.02.032↗
  22. Reappraisal of Total Pancreatectomy in 45 Patients With Pancreatic Ductal Adenocarcinoma in the Modern Era Using Matched-Pairs Analysis: Multicenter Study Grou… Co-author DOI 10.1097/mpa.0000000000000579↗
  23. [Neoadjuvant Chemotherapy Using S-1 for Pancreatic Cancer - Mid-Term Results]. First author PMID 27760934↗
  24. Postoperative prognosis of pancreatic cancer with para-aortic lymph node metastasis: a multicenter study on 822 patients. Co-author DOI 10.1007/s00535-014-1005-4↗
  25. Reappraisal of peritoneal washing cytology in 984 patients with pancreatic ductal adenocarcinoma who underwent margin-negative resection. Co-author DOI 10.1007/s11605-014-2637-7↗
  26. Proposed preoperative risk factors for early recurrence in patients with resectable pancreatic ductal adenocarcinoma after surgical resection: A multi-center r… Co-author DOI 10.1016/j.pan.2015.09.008↗
  27. Impact of Preoperative Biliary Drainage on Long-Term Survival in Resected Pancreatic Ductal Adenocarcinoma: A Multicenter Observational Study. Co-author DOI 10.1245/s10434-015-4618-9↗
  28. Influence of preoperative anti-cancer therapy on resectability and perioperative outcomes in patients with pancreatic cancer: project study by the Japanese Soc… Co-author DOI 10.1002/jhbp.15↗
  29. Pancreatic cancer causing acute pancreatitis: a comparative study with cancer patients without pancreatitis and pancreatitis patients without cancer. Last author DOI 10.1007/s00534-013-0598-y↗

Closest collaborators

The 25 strongest of 120 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Sohei Satoi · 20 shared papers, 2014–2026 · strength 1.76
  2. Michiaki Unno · 20 shared papers, 2014–2026 · strength 1.70
  3. Hiroki Yamaue · 16 shared papers, 2014–2026 · strength 1.26
  4. Masayuki Sho · 16 shared papers, 2014–2026 · strength 1.24
  5. Masataka Kikuyama · 4 shared papers, 2019–2026 · strength 1.13
  6. Yoshiaki Murakami · 14 shared papers, 2014–2026 · strength 1.05
  7. Ippei Matsumoto · 15 shared papers, 2014–2025 · strength 0.98
  8. Fuyuhiko Motoi · 16 shared papers, 2014–2022 · strength 0.97
  9. Satoshi Hirano · 5 shared papers, 2022–2026 · strength 0.91
  10. Itaru Endo · 4 shared papers, 2025–2026 · strength 0.79
  11. Masanao Kurata · 14 shared papers, 2013–2019 · strength 0.73
  12. Kenichiro Uemura · 12 shared papers, 2015–2022 · strength 0.70
  13. Masamichi Mizuma · 7 shared papers, 2015–2025 · strength 0.64
  14. Masayuki Ohtsuka · 3 shared papers, 2025–2026 · strength 0.60
  15. Manabu Kawai · 9 shared papers, 2015–2025 · strength 0.57
  16. Hiroaki Yanagimoto · 10 shared papers, 2015–2019 · strength 0.55
  17. Takumi Fukumoto · 10 shared papers, 2015–2019 · strength 0.51
  18. Suguru Yamada · 3 shared papers, 2017–2026 · strength 0.50
  19. Pradez Sapkota · 1 shared paper, 2026 · strength 0.50
  20. Kazuro Chiba · 3 shared papers, 2013–2025 · strength 0.48
  21. Jun Nakahodo · 2 shared papers, 2019–2025 · strength 0.46
  22. Shuji Isaji · 2 shared papers, 2025–2026 · strength 0.44
  23. Masanori Oshi · 2 shared papers, 2025–2026 · strength 0.44
  24. Takashi Murakami · 2 shared papers, 2025–2026 · strength 0.44
  25. Yasuhiro Yabushita · 2 shared papers, 2025–2026 · strength 0.44

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.